Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:CTMX NASDAQ:EPIX NASDAQ:INBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.25+0.8%$2.97$1.05▼$3.97$362.25M1.92712,621 shs724,346 shsCTMXCytomX Therapeutics$2.05-1.0%$2.25$0.40▼$3.10$341.37M2.133.92 million shs1.58 million shsEPIXESSA Pharma$0.24-4.3%$1.72$0.22▼$7.88$11.62M1.5515.65 million shs10.19 million shsINBXInhibrx Biosciences$27.88+1.8%$21.24$10.81▼$28.16$396.89M0.24103,597 shs126,178 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+0.62%+4.51%+12.87%+4.68%+10.75%CTMXCytomX Therapeutics-0.97%+0.99%-8.89%-18.65%+76.72%EPIXESSA Pharma-4.32%-87.76%-87.43%-86.01%-95.52%INBXInhibrx Biosciences+1.75%+15.40%+14.92%+105.60%+99.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.3776 of 5 stars3.51.00.00.00.60.80.6CTMXCytomX Therapeutics4.218 of 5 stars3.51.00.04.72.81.71.3EPIXESSA Pharma3.2502 of 5 stars3.03.00.00.03.13.31.3INBXInhibrx Biosciences1.6412 of 5 stars0.03.00.04.62.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75138.83% UpsideCTMXCytomX Therapeutics 3.00Buy$5.75180.49% UpsideEPIXESSA Pharma 2.00Hold$2.00751.06% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest EPIX, INBX, ADCT, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M5.15N/AN/A($1.77) per share-1.83CTMXCytomX Therapeutics$138.10M2.45$0.36 per share5.72$0.73 per share2.81EPIXESSA PharmaN/AN/AN/AN/A$2.30 per shareN/AINBXInhibrx Biosciences$1.40M288.46$121.22 per share0.23$4.73 per share5.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.563.66N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/AINBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)Latest EPIX, INBX, ADCT, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025EPIXESSA Pharma-$0.17-$0.09+$0.08-$0.09N/AN/A8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ALatest EPIX, INBX, ADCT, and CTMX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66CTMXCytomX TherapeuticsN/A4.204.20EPIXESSA PharmaN/A69.0669.06INBXInhibrx Biosciences1.454.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CTMXCytomX Therapeutics67.77%EPIXESSA Pharma75.12%INBXInhibrx Biosciences82.46%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%CTMXCytomX Therapeutics6.60%EPIXESSA Pharma15.50%INBXInhibrx Biosciences17.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableINBXInhibrx Biosciences16614.49 million12.01 millionOptionableEPIX, INBX, ADCT, and CTMX HeadlinesRecent News About These CompaniesGroupe la Francaise Purchases New Position in Inhibrx Biosciences, Inc. $INBXAugust 27 at 5:56 AM | marketbeat.comInhibrx Biosciences Reports Q2 2025 Financial ResultsAugust 26 at 12:10 AM | tipranks.comInhibrx Biosciences (NASDAQ:INBX) Receives Market Perform Rating from JMP SecuritiesAugust 25, 2025 | americanbankingnews.comInhibrx Biosciences' (INBX) "Market Perform" Rating Reiterated at JMP SecuritiesAugust 24, 2025 | marketbeat.comHighTower Advisors LLC Acquires 90,002 Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX)August 19, 2025 | marketbeat.comInhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to "Hold" RatingAugust 19, 2025 | americanbankingnews.comInhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to Hold RatingAugust 18, 2025 | marketbeat.comInhibrx Biosciences (NASDAQ:INBX) Releases Earnings Results, Beats Estimates By $1.07 EPSAugust 15, 2025 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deXTX Topco Ltd Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)August 14, 2025 | marketbeat.comInhibrx Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | prnewswire.comInhibrx Biosciences (INBX) Projected to Post Earnings on TuesdayAugust 6, 2025 | marketbeat.comInhibrx Biosciences Advances HexAgon-HN Study for Head, Neck CancerJuly 29, 2025 | msn.comInhibrx Biosciences: Seeing Soon If The Momentum Is Just HypeJuly 18, 2025 | seekingalpha.comNoteworthy Tuesday Option Activity: INBX, ODP, AZO | NasdaqJuly 10, 2025 | nasdaq.comINBX - Inhibrx Biosciences Inc Executives - MorningstarJuly 2, 2025 | morningstar.comMInhibrx Biosciences, Inc. (INBX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comInhibrx Biosciences Inc (INBX) - Investing.comJune 25, 2025 | investing.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deInhibrx Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPIX, INBX, ADCT, and CTMX Company DescriptionsADC Therapeutics NYSE:ADCT$3.24 +0.03 (+0.78%) Closing price 08/28/2025 03:59 PM EasternExtended Trading$3.26 +0.02 (+0.62%) As of 08/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.CytomX Therapeutics NASDAQ:CTMX$2.05 -0.02 (-0.97%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.12 +0.07 (+3.17%) As of 08/28/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.ESSA Pharma NASDAQ:EPIX$0.24 -0.01 (-4.32%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.23 0.00 (-2.13%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Inhibrx Biosciences NASDAQ:INBX$27.88 +0.48 (+1.75%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$27.88 0.00 (0.00%) As of 08/28/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.